According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients
The post FDA approves Grifols’ Xembify to treat primary immunodeficiencies appeared first on Pharmaceutical Business review.
Original Article: FDA approves Grifols’ Xembify to treat primary immunodeficiencies